Pharmaceutical contract manufacturing lets drug companies bring products to market without building and validating their own plants. For sterile injectables, large-volume parenterals, and other critical therapies, the right manufacturing partner affects more than cost. It shapes product quality, regulatory outcomes, operator safety, and how reliably patients can get the medicine.
This guide explains how pharmaceutical contract manufacturing works, the dosage forms and technologies that matter most, why terminal sterilization matters, what specialized production such as high-potency and antibiotic manufacturing requires, and how to evaluate a contract manufacturing organization (CMO) for your product.
What Is Pharmaceutical Contract Manufacturing?
A pharmaceutical CMO produces finished drug products, or specific stages of production, on behalf of a brand owner. The brand owner keeps ownership of the product and its regulatory filings. The CMO supplies the facilities, equipment, trained staff, and quality systems needed to manufacture under current Good Manufacturing Practice (cGMP).
Companies outsource pharmaceutical manufacturing for several reasons:
Capital: Sterile and high-containment facilities cost hundreds of millions of dollars to build and years to qualify.
Speed: An established, validated line shortens the path from development to commercial supply.
Specialized capability: Technologies such as in-house container production, terminal sterilization, and dedicated containment suites are difficult to justify for a single product.
Capacity: A CMO can absorb demand spikes and support launches across several markets.
Focus: Internal teams can concentrate on research, regulatory strategy, and commercialization.
In the United States, finished drug manufacturing is governed by 21 CFR Parts 210 and 211. Whether production happens in-house or at a CMO, the brand owner is responsible for making sure the product meets those requirements, which is why partner selection carries so much weight.
Core Pharmaceutical Dosage Forms and Technologies
Each dosage form calls for different equipment, environmental controls, and validation work. Knowing what your product needs narrows the list of qualified partners quickly.
Sterile Injectables and Parenteral Solutions
Injectable products bypass the body's natural defenses, so sterility and particulate control are critical. Production takes place in classified cleanrooms with strict environmental monitoring, validated sterilization or aseptic processes, and 100% visual inspection of filled units. Common formats include vials, ampoules, prefilled containers, and large-volume IV bags.
Large-volume parenterals, such as IV fluids and dialysis solutions, add another requirement: very high throughput with consistent fill accuracy and container integrity. Manufacturers that produce their own bags and containers in-house, then fill and sterilize them on site, remove supplier handoffs that can slow production or introduce quality risk.
Terminal Sterilization
Terminal sterilization means the product is filled and sealed in its final container and then sterilized inside the container, most often with moist heat in an autoclave. Beacuase sterilization happens after the container is closed, it provides a higher and more measurable sterility assurance level than aseptic processing, where the product and components are sterilized separately and then assembled in a controlled environment. Regulators, including FDA and EU GMP Annex 1, generally expect terminal sterilization to be used wherever the product and its container can withstand it.
For large-volume solutions in flexible bags or rigid contaners, terminal sterilization is usually the most robust path. It does require container materials, such as PVC, PP, EVA or multilayer films, and closures validated to withstand the cycle without compromising container integrity, extractables profile, or appearance. That is why container design and sterilization validation should be planned together from the start.
Blow-Fill-Seal (BFS)
Blow-fill-seal is an automated aseptic process that forms a plastic container, fills it, and seals it in one continuous operation inside a controlled environment. Because the container is created and closed within seconds, with little human involvement, BFS reduces contamination risk compared with conventional filling of pre-made containers.
BFS is widely used for ampoules, vials, and bottles of sterile solutions, including respiratory, ophthalmic, and injectable products. FDA's aseptic processing guidance includes a dedicated appendix on BFS, and the 2022 revision of EU GMP Annex 1 encourages technologies that reduce direct operator intervention. For high-volume sterile liquids, BFS often offers lower unit costs and simpler supply chains than glass. When the formulation can tolerate heat, however, filling into flexible or rigid containers followed by terminal sterilization remains the preferred route.
Lyophilized Powders
Many drugs, including biologics and some oncology compounds, are unstable in liquid form. Lyophilization (freeze-drying) removes water at low temperature and pressure, producing a stable powder that is reconstituted before use. Lyophilization cycles must be carefully developed and validated, and equipment capacity is often a bottleneck.
Oral Solids and Oral Solutions
Tablets and capsules remain the most common dosage forms. Production involves blending, granulation, compression or encapsulation, coating, and packaging, often in blister packs or bottles. At commercial scale, the priorities are content uniformity, dissolution performance, and efficient high-volume packaging. Oral solutions add formulation and filling steps similar to those used for other liquids.
High-Potency Manufacturing: Oncology and Immunosuppressants
Oncology drugs and immunosuppressants are often classified as highly potent active pharmaceutical ingredients (HPAPIs). Very small exposures can harm workers, and trace carryover can contaminate other products. Manufacturing them safely depends on containment designed into the facility from the start, not added afterward.
The industry uses Occupational Exposure Bands (OEBs) to classify compounds by potency and toxicity. OEB 5 is the most stringent band in common use, typically for compounds with occupational exposure limits below 1 microgram per cubic meter of air. Exact band definitions vary by company, so confirm how any partner defines its ratings.
Key containment features to look for in an HPAPI facility include:
Closed processing: Isolators for sampling, dispensing, and weighing, plus sealed transfer bins between steps.
Dedicated air handling: Independent HVAC that prevents air from crossing between production areas.
Automated cleaning: Clean-in-place (CIP) and wash-in-place (WIP) systems that reduce operator exposure and produce repeatable, validated results.
Decontamination: Vaporized hydrogen peroxide (VHP) systems for rooms and equipment.
Dedicated utilities: Separate water purification and support systems to prevent cross-contamination.
A facility built to a high containment standard throughout, rather than in isolated suites, gives more flexibility when product mix or volume changes.
Antibiotic Manufacturing: Why Segregation Matters
Penicillins and other beta-lactam antibiotics can trigger severe allergic reactions in sensitive patients, even at trace levels. For this reason, FDA regulations (21 CFR 211.42(d)) require penicillin manufacturing to take place in facilities separate from those used for other human drug products. FDA guidance also recommends similar separation for non-penicillin beta-lactams, such as cephalosporins.
For brand owners, this means antibiotic products cannot simply be placed on any available line. They need a partner with dedicated, segregated facilities for each antibiotic class, with separate air handling, personnel flows, and equipment.
The Pharmaceutical Manufacturing Lifecycle with a CMO
Most CMO relationships follow a similar sequence, although timelines vary with product complexity and regulatory pathway.
Feasibility and technical assessment: The CMO reviews the formulation, process, analytical methods, and volume forecasts to confirm fit and identify gaps.
Technology transfer: Process knowledge, specifications, and methods move from the brand owner or development site to the manufacturing site. Clear documentation at this stage prevents most later delays.
Scale-up and engineering batches: Trial runs confirm that the process performs at commercial scale on the CMO's equipment.
Process validation: Equipment qualification (IQ/OQ/PQ) and process performance qualification batches show that the process consistently produces product that meets specifications.
Stability studies and regulatory filings: Data from registration batches supports submissions or post-approval site changes.
Commercial manufacturing: Routine production under the quality agreement, with batch release, deviation management, change control, and continuous improvement.
A written quality agreement should define each party's responsibilities for batch release, deviations, complaints, change control, and audits before commercial production begins.
How to Evaluate a Pharmaceutical CMO
The criteria in our guide How to Choose a CMO Partner apply to pharmaceutical products as well. The following points carry extra weight for drug manufacturing:
Regulatory standing: Inspection history with the agencies in your target markets, current registrations, and how the site handled past observations.
Dosage-form fit: Proven experience with your specific format, such as large-volume flexible bags, rigid containers, or terminally sterilized solutions.
Containment and segregation: Verified OEB capability for potent compounds and dedicated facilities for beta-lactam antibiotics.
Capacity and scalability: Room to grow from launch volumes to peak demand without moving to another site.
Vertical integration: In-house container production, filling, sterilization, and packaging reduce handoffs, lead times, and supply risk.
Data integrity and digital systems: Electronic batch records and connected quality systems improve traceability and make audits easier.
Location and logistics: Distance to your markets affects freight cost, lead times, cold chain complexity, and how easily your team can visit the site.
For companies supplying North America, manufacturing in Mexico offers shorter transit times than Asia, time-zone alignment with U.S. teams, and trade benefits under the United States-Mexico-Canada Agreement (USMCA).
How PiSA USA Supports Pharmaceutical Manufacturing
PiSA USA is the commercial brand of PiSA Manufacturing, part of Grupo PiSA, a pharmaceutical and medical device manufacturer with more than 80 years of history serving healthcare markets in Mexico, the United States, Latin America, and the Caribbean. Grupo PiSA operates 17 manufacturing plants and more then 445,000 square meters (about 4.8 million square feet) of infrastructure in Mexico. From its Guadalajara Operations, PiSA’s contract manufacturing offering for the U.S.market centers on terminally sterilized solutions, the flexible and rigid containers that hold them, and the administration sets that accompany them.
Sterile Solutions and Terminal Sterilization
Large-volume parenteral solutions: IV fluids such as saline, lactated Ringer’s, and dextrose, plus irrigation, wound-care, and dialysis solutions.
Ophthalmic irrigation solutions: Large-volume balanced saline solutions and their containers, including empty bags.
Custom containers: PVC, PP, and EVA bags, including multi-chamber designs, supplied empty or filled, plus bottles and ampoules for terminally sterilized products.
Administration and tube sets: IV administration sets and tube sets in PVC, with or without DEHP.
In-house sterilization: Moist-heat (autoclave) terminal sterilization and ethylene oxide (EtO) sterilization on site.
Vertical integration: Film and tubing extrusion, container conversion, filling, sterilization, and packaging under one quality system, which shortens lead times and removes supplier handoffs.
Regulatory model: FDA-registered manufacturing. The brand owner holds the 510(k) or drug application, and PiSA manufactures to the brand owner’s specifications.
Grupo PiSA’s Own Portfolio
Grupo PiSA also runs dedicated operations for its own brands, including an oncology and immunosuppressant facility opened in 2023 on its Tlajomulco campus, blow-fill-seal and lyophilization lines, segregated beta-lactam antibiotic plants, oral solid dose manufacturing, and biotechnology. These operations are committed to Grupo PiSA’s own portfolio and markets. For U.S. brand owners, this division of focus keeps our contract manufacturing teams, lines, and quality resources dedicated to sterile solutions and the containers and sets that go with them.
Because PiSA also manufactures medical devices, including injection-molded components, extruded tubing and film, and finished assemblies, it can support combination products that bring a drug and a delivery device together under one quality system.
Conclusion
Choosing a pharmaceutical contract manufacturer is a long-term decision. The right partner brings the specific technologies your product needs, the sterilization approach and quality controls to make it safely, the capacity to grow with demand, and a quality culture that holds up under inspection. Brand owners who define their requirements early, including dosage form, potency, volumes, and target markets, can narrow the field quickly and avoid costly site changes later.
To discuss your pharmaceutical manufacturing needs, contact the PiSA USA team.
